AI-generated summaries. Verify every claim with the cited sources before acting on them. Read our methodology

← Back to all reports

Fabry Disease

Recent research efforts aimed at curing Fabry Disease.

Last updated
Also available in
Français — Maladie de Fabry

Fabry Disease

Overview

Fabry disease is a rare inherited disorder caused by disease-causing variants in the GLA gene, which reduce or eliminate the activity of the enzyme alpha-galactosidase A (α-Gal A). Without enough α-Gal A, fatty molecules called globotriaosylceramide (Gb3) and lyso-Gb3 accumulate in cells, gradually damaging the kidneys, heart, blood vessels, nerves, skin, eyes, and gastrointestinal system. Because the condition is X-linked, males with classic Fabry disease often develop severe, earlier disease, while females can have anything from few symptoms to substantial organ involvement. Current therapies review (pmc.ncbi.nlm.nih.gov)

Symptoms may begin with burning limb pain, reduced sweating, heat intolerance, stomach symptoms, and skin lesions, but long-term prognosis is principally shaped by kidney failure, cardiomyopathy, arrhythmia, stroke, and fibrosis—permanent scarring—of affected organs. Current care aims to slow rather than reverse disease: enzyme replacement therapy (ERT) supplies α-Gal A by regular intravenous infusion, while migalastat is an oral “pharmacological chaperone” that can stabilize certain responsive mutant enzymes. Supportive treatment for kidney, cardiac, neurologic, and pain complications remains essential, and earlier treatment generally produces better outcomes than treatment begun after irreversible injury. Current therapies review (pmc.ncbi.nlm.nih.gov)

Scope of Recent Research (2020–present)

Fabry research since 2020 has been especially active in one-time gene therapies designed to turn the liver, blood-forming cells, or heart into a sustained source of α-Gal A. The central questions are whether enough enzyme can be produced for years, whether it reaches difficult organs such as kidney and heart, and whether immune and vector-related toxicity can be controlled. The field is closer than it has been to a potentially disease-modifying one-time treatment, but no therapy has yet established that it permanently corrects Fabry disease or reverses established organ damage. Progress and challenges review (pmc.ncbi.nlm.nih.gov)

Major Breakthroughs and Emerging Therapies

In vivo AAV gene addition is the leading curative strategy. These treatments use adeno-associated virus (AAV) vectors to deliver a working GLA gene, generally to liver cells, so the liver releases α-Gal A into the bloodstream for uptake by other tissues. Isaralgagene civaparvovec (ST-920), originally developed by Sangamo and acquired by PTC Therapeutics in September 2026, is an AAV2/6 liver-directed therapy and the most advanced program. In the Phase 1/2 STAAR study, PTC reports sustained enzyme expression, withdrawal of participants from ERT, and renal-function results that support a planned accelerated-approval biologics license application submission in the fourth quarter of 2026; these findings remain based on an open-label early-phase study and require regulatory review and longer-term confirmation. PTC acquisition update (ir.ptcbio.com)

Other AAV programs illustrate different delivery strategies. AMT-191, from uniQure, uses an AAV5 vector and a liver-specific promoter; its Phase I/IIa study began enrolling in 2024. 4D-310 was designed to preferentially target the heart, an important approach because cardiac disease can progress despite ERT, but its early clinical development exposed a major safety warning: three of six treated participants developed atypical hemolytic uremic syndrome, a serious blood-vessel and kidney complication. The U.S. Food and Drug Administration lifted the related clinical hold in August 2024, but the event emphasizes that direct cardiac delivery and high-dose systemic AAV require exceptional caution. AMT-191 program Progress and challenges review (uniqure.com)

Ex vivo stem-cell gene therapy has generated the strongest long-duration human evidence outside of AAV. In the Canadian FACTs study, researchers collected participants’ own CD34-positive blood-forming stem and progenitor cells, inserted an α-Gal A gene with a lentiviral vector, and reinfused the corrected cells after reduced-intensity conditioning chemotherapy. Five-year results in five men found persistent enzyme production and durable gene-marked blood cells; three participants stopped ERT, four had lower plasma lyso-Gb3, and no clonal dominance—a warning sign for a potential blood-cancer risk—was detected. This approach may offer durable systemic enzyme production, but it remains intensive because it requires cell collection, specialized manufacturing, and chemotherapy conditioning. FACTs five-year results (onlinelibrary.wiley.com)

Gene editing and RNA-based treatments remain preclinical. A 2021 mouse study used zinc-finger nucleases to insert a human GLA sequence into the liver’s albumin “safe-harbor” locus, producing high α-Gal A activity and reducing Fabry substrate; unlike conventional AAV gene addition, editing aims to make a permanent, targeted DNA change. Researchers are also investigating messenger RNA packaged in lipid nanoparticles and nonviral DNA particles, which could direct temporary α-Gal A production without permanently changing DNA. These concepts could eventually permit repeat dosing or avoid some viral-vector constraints, but they have not yet demonstrated curative clinical benefit in people with Fabry disease. ZFN editing in Fabry mice Progress and challenges review (pubmed.ncbi.nlm.nih.gov)

Substrate-reduction therapies are not genetic cures, but they test whether reducing production of disease lipids can complement enzyme restoration. Venglustat, an inhibitor of glucosylceramide synthesis, lowered lipid-pathway biomarkers in a small open-label Phase 2 study, although larger studies are needed to establish clinical benefit. Conversely, the randomized Phase 3 MODIFY study of lucerastat lowered plasma Gb3 but did not improve its primary endpoint of neuropathic pain at six months. Together, these results show that biomarker reduction alone cannot yet be assumed to translate into meaningful clinical improvement. Venglustat Phase 2 study Lucerastat Phase 3 study (pmc.ncbi.nlm.nih.gov)

Clinical Trials and Experimental Approaches

The pivotal current program is the completed Phase 1/2 STAAR study of ST-920, a single-dose, dose-ranging AAV2/6 therapy. In a February 2025 sponsor update covering 23 participants with at least one year of follow-up, Sangamo reported a positive mean annualized estimated glomerular filtration rate (eGFR) slope, sustained α-Gal A activity, stable lyso-Gb3 after ERT withdrawal, and no treatment discontinuations or deaths attributed to treatment; all 18 participants who entered on ERT reportedly remained off ERT at that cutoff. These are promising but preliminary, non-randomized data. As of October 15, 2026, PTC owns the program and expects to complete its rolling U.S. biologics license application in the fourth quarter of 2026. STAAR Phase 1/2 update PTC acquisition update (investor.sangamo.com)

The other notable active early-stage trials are uniQure’s Phase I/IIa AMT-191 liver-directed AAV5 study and 4D Molecular Therapeutics’ Phase 1/2 4D-310 program for Fabry disease with cardiac involvement. Freeline’s liver-directed FLT190 program established encouraging preclinical correction of Fabry biomarkers in mice, but its MARVEL-1 clinical program was terminated in 2023 as the company refocused resources. The Canadian FACTs lentiviral stem-cell study is completed and provides five-year follow-up data, whereas Avrobio’s related stem-cell program was discontinued after variable engraftment and strategic reprioritization. AMT-191 program FLT190 preclinical study Progress and challenges review FACTs five-year results (uniqure.com)

Methodologies and Scientific Approaches

Researchers use Gla-deficient mice, patient cells, and nonhuman primates to test whether a treatment raises α-Gal A activity, lowers Gb3 and lyso-Gb3, and clears stored lipid from kidney, heart, blood vessels, and other organs. Liver-directed programs optimize AAV capsids, liver-specific promoters, and codon-optimized GLA sequences to turn hepatocytes into long-term enzyme factories; successful “cross-correction” requires secreted enzyme to be taken up by distant diseased cells. Kidney biopsies, plasma and urine lipid biomarkers, eGFR slope, cardiac magnetic resonance imaging, echocardiography, exercise capacity, and patient-reported quality-of-life measures are then used to test whether biochemical correction is reaching clinically important organs. FLT190 preclinical study Progress and challenges review (nature.com)

Cell-based studies add measurements of vector-copy number, long-term engraftment, integration sites, and clonal behavior to determine whether corrected stem cells persist safely. Gene-editing studies evaluate on-target insertion, unintended edits, liver expression, and substrate clearance, while nanoparticle-based RNA and DNA approaches focus on organ distribution, repeat-dose feasibility, and whether transient enzyme production can reach heart and kidney. FACTs five-year results ZFN editing in Fabry mice (onlinelibrary.wiley.com)

Leading Institutions and Funding

PTC Therapeutics now leads late-stage development of ST-920 after completing its acquisition from Sangamo on September 21, 2026. The transaction involved $111 million in cash at closing and up to $100 million in regulatory milestones, demonstrating the commercial interest in a potential one-time Fabry treatment. uniQure is advancing AMT-191, 4D Molecular Therapeutics has pursued heart-targeted AAV delivery, and the Canadian FACTs trial brought together the M.A.G.I.C. Clinic in Calgary, the University of Toronto, the Medical College of Wisconsin, Western University, and the Université de Sherbrooke. PTC acquisition update FACTs five-year results AMT-191 program (ir.ptcbio.com)

Public and charitable support remains important because Fabry trials are small and technically demanding. The FACTs study reports support from the Canadian Institutes of Health Research, the Kidney Foundation of Canada, the MACC Fund, and Avrobio. In the United States, an NIH Small Business Innovation Research Phase I award of $295,923 supported Kinetiq Therapeutics’ preclinical work on a self-administered subcutaneous ERT concept, an example of funding aimed at reducing treatment burden even when it is not itself curative. FACTs five-year results NIH SBIR award (pmc.ncbi.nlm.nih.gov)

Strengths, Limitations, and Challenges

The major strength of gene addition is biological plausibility: Fabry disease results from deficient activity of one enzyme, and even modest restoration of enzyme activity can reduce stored substrate. The ST-920 and FACTs results provide early evidence that one intervention can sustain α-Gal A production for years and allow some participants to stop chronic ERT. However, trials remain small, largely open-label, and enriched for selected adults, so they cannot yet prove durable prevention of kidney failure, stroke, arrhythmia, or death across the broad Fabry population, including children and people with advanced disease. STAAR Phase 1/2 update FACTs five-year results (investor.sangamo.com)

Safety and access are equally important barriers. AAV therapies can be limited by pre-existing antibodies, immune responses to the vector or newly produced enzyme, liver inflammation, and inability to redose after anti-AAV antibodies develop; the 4D-310-associated atypical hemolytic uremic syndrome demonstrates that serious toxicity can occur. Stem-cell approaches avoid some AAV limitations but introduce chemotherapy, manufacturing complexity, and theoretical risks from lentiviral DNA integration. Even a successful therapy may not erase fibrosis or repair organs already damaged before treatment, and the high cost and specialist infrastructure for one-time gene therapies could worsen unequal access unless addressed deliberately. Progress and challenges review Current therapies review (pmc.ncbi.nlm.nih.gov)

Outlook and Future Directions

As of October 15, 2026, Fabry disease has no proven cure, but ST-920 is the closest candidate to a one-time treatment that could substantially reduce dependence on ERT; the immediate milestone is completion of its planned fourth-quarter 2026 U.S. biologics license application and subsequent regulatory review. Longer-term milestones are more demanding: confirmation that kidney benefit persists beyond two years, demonstration of meaningful cardiac and neurologic protection, safety follow-up over many years, and evidence that therapy benefits women, children, and people with advanced organ disease. Gene editing, redosable RNA delivery, improved cardiac targeting, and stem-cell approaches could broaden the path to a true cure, but each remains earlier and must first demonstrate durable clinical benefit with acceptable safety. PTC acquisition update Progress and challenges review (ir.ptcbio.com)

References

Don't see your disease? Request a report